Volume 29, Number 1—January 2023
Research
Effects of Second Dose of SARS-CoV-2 Vaccination on Household Transmission, England
Table
Period | Vaccine | Analysis model HR (95% CI) |
||||
---|---|---|---|---|---|---|
A, never vaccinated | B, not vaccinated before index case | C, vaccinated after index case | D, unvaccinated contacts only | E, cohort | ||
Feb-May | ChAdOx1 | 0.54 (0.41–0.69) | 0.50 (0.38–0.64) | 0.50 (0.38–0.65) | 0.48 (0.37–0.64) | 0.53 (0.43–0.66) |
BNT162b2 |
0.19 (0.13–0.28) |
0.18 (0.12–0.26) |
0.18 (0.12–0.26) |
0.14 (0.09–0.23) |
0.19 (0.13–0.26) |
|
Jun-Sep | ChAdOx1 | 1.06 (1.04–1.08) | 1.06 (1.04–1.08) | 0.94 (0.88–1.00) | 0.84 (0.76–0.92) | 1.08 (1.06–1.10) |
BNT162b2 | 0.74 (0.72–0.76) | 0.74 (0.73–0.76) | 0.66 (0.62–0.71) | 0.56 (0.51–0.62) | 0.76 (0.74–0.78) | |
mRNA-1273 | 0.36 (0.29–0.45) | 0.36 (0.29–0.45) | 0.31 (0.25–0.39) | 0.30 (0.22–0.40) | 0.380.30–0.47) |
*For models A–D, we used a stratified Cox model with adjustment, and different inclusion criteria for contacts and of the baseline group of contacts of unvaccinated index cases. Model E has the same inclusion criteria as model A, but uses a cohort model with all covariates entered as adjustment variables, rather than stratification. HR, hazard ratio.
Page created: December 09, 2022
Page updated: December 21, 2022
Page reviewed: December 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.